Basal and TRH stimulated serum levels of TSH in patients with hyperprolactinaemia and in subjects on oestrogen treatment

1983 ◽  
Vol 102 (2) ◽  
pp. 173-178 ◽  
Author(s):  
Eva M. Erfurth ◽  
Pavo Hedner ◽  
Anders Nilsson
Keyword(s):  
Serum Level ◽  
Serum Levels ◽  
Plasma Prolactin ◽  
Thyroid Antibodies ◽  
Elevated Plasma ◽  
Oestrogen Treatment ◽  
Pituitary Dysfunction ◽  
Basal Serum ◽  
The Mean ◽  
Serum Tsh

Abstract. In 21 hyperprolactinaemic patients without other signs of pituitary dysfunction the mean basal serum level of TSH was 4.4 ± 0.47 μU/ml that was significantly (P < 0.001) higher than controls (2.5 ± 0.16 μU/ml and oestrogen treated individuals (2.4 ± 0.29 μU/ml). The TSH increase was more pronounced (P < 0.05) in hyperprolactinaemic patients without sellar enlargement and with moderately elevated plasma prolactin levels (155 ± 42 μg/ml) than in patients with sellar enlargement and higher plasma prolactin levels (857 ± 306 μg/ml). The serum levels of thyroxine and triiodothyronine in the hyperprolactinaemic patients did not differ significantly from controls. Patients with thyroid antibodies were excluded. The increased basal serum level of TSH in hyperprolactinaemia is compatible with the concept of a reduced dopaminergic tonus as the mechanism for both changes. In patients with advanced hyperprolactinaemia and sellar enlargement the high prolactin level may induce some inhibition of TSH release and explain their lower basal serum level of TSH that was probably not due to pituitary compression as they responded normally to TRH. The TSH response to TRH was significantly (P < 0.05) correlated to the basal serum TSH in all groups. The regression lines were very similar for hyperprolactinaemic patients and controls suggesting that in hyperprolactinaemia the thyrotroph has not changed its mode of response to TRH. In contrast, oestrogen treated subjects in addition to dependence on basal serum TSH levels showed a genuinely augmented response to TRH (164.6 ± 20.3%, P < 0.01) compared to controls.

SERUM THYROTROPHIN, PROLACTIN AND GROWTH HORMONE, RESPONSE TO TRH DURING OESTROGEN TREATMENT

1977 ◽  
Vol 84 (1) ◽  
pp. 23-35 ◽  
Author(s):  
E. Rutlin ◽  
E. Haug ◽  
P. A. Torjesen
Keyword(s):  
Growth Hormone ◽  
Human Subjects ◽  
Serum Levels ◽  
Normal Male ◽  
Oestrogen Treatment ◽  
Thyrotrophin Releasing Hormone ◽  
Basal Serum ◽  
Menopausal Women ◽  
Menstruating Women ◽  
Post Menopausal

ABSTRACT The serum levels of thyrotrophin (TSH), prolactin (PRL) and growth hormone (GH) and the response of these hormones to 500 μg thyrotrophin-releasing hormone (TRH) iv were studied in menstruating women. in post-menopausal women before and after 2 mg oestradiol valerate for 5 consecutive days, and in men on long term oestrogen treatment. Oestrogen treatment had no effect on basal serum TSH levels, which were within the normal range in all groups. The TSH response to TRH was not different in menstruating and post-menopausal women and was not changed in the latter group after oestrogen treatment. In men treated chronically with oestrogens, the TSH response to TRH was similar to that found in normal male subjects. There was no difference in basal levels of serum PRL between males and menstruating females. In the post-menopausal women, however, basal levels of serum PRL was significantly decreased, but rose during oestrogen treatment to serum levels normally found in menstruating women. In the oestrogen treated males basal serum PRL levels were significantly higher than in untreated men. The PRL response to TRH was significantly greater in females than in males, but in the oestrogen treated males the PRL response to TRH was greatly increased and almost of the same magnitude as the response in females. There was no difference in PRL response between menstruating and post-menopausal women, and oestrogen treatment of the latter group had no significant effect on the PRL response. Basal levels of serum GH did not differ between the groups. In the group of 9 post-menopausal women one subject showed a small GH response to TRH prior to oestrogen treatment, while 7 subjects showed GH responses to TRH after oestrogen treatment. In the group of 5 chronically oestrogen treated men, 2 subjects had increased serum levels of GH after TRH. Thus our data show that oestrogen administration may induce PRL release in human subjects, while oestrogens seem to play a far less important role in the regulation of GH and TSH secretion.

scholarly journals Hubungan Kadar LDL dan HDL Serum Ibu Hamil Aterm dengan Berat Lahir Bayi

2014 ◽  
Vol 3 (3) ◽  
Author(s):  
Oktalia Sabrida ◽  
Hariadi Hariadi ◽  
Eny Yantri
Keyword(s):  
Birth Weight ◽  
Serum Level ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Serum Levels ◽  
Term Pregnancy ◽  
Cross Sectional ◽  
Consecutive Sampling ◽  
The Mean ◽  
Infant Birth

AbstrakAda anyak penelitian yang membuktikan transfer kolesterol dari ibu ke janin melalui lapisan trofoblas yang membawa partikel LDL (Low Density Lipoprotein) dan HDL (High Density Lipoprotein). Pengambilan dan pemanfaatan LDL oleh plasenta merupakan mekanisme alternatif oleh janin untuk memperoleh asam lemak dan asam amino esensial. Tujuan penelitian ini untuk mengetahui hubungan kadar LDL dan HDL serum ibu hamil aterm dengan berat lahir bayi. Penelitian ini merupakan studi observasional dengan rancangan cross sectional. Dilakukan pemeriksaan kadar LDL dan HDL serum terhadap 31 sampel ibu hamil aterm yang dipilih secara consecutive sampling, kemudiaan saat bayi dari sampel lahir dilakukan penimbangan berat lahir bayi dalam 1 jam setelah lahir dengan keadaan tanpa pakaian. Data dianalisis menggunakan uji korelasi Pearson dilanjutkan dengan uji regresi linier sederhana, nilai p<0.05 dianggap bermakna secara statistik. Rerata kadar LDL serum ibu hamil aterm 138,52±37,86 mg/dl dengan 7 sampel (22,60%) kadar LDL <101 mg/dl. Rerata kadar HDL serum ibu hamil aterm 53,32±17,39 mg/dl dengan 13 sampel (41,90%) kadar HDL <48 mg/dl. Rerata berat lahir bayi 3150,00±489,89 gram dengan 2 sampel (6,50%) memiliki bayi dengan berat<2500 gram. Terdapat hubungan positif antara kadar LDL serum ibu hamil aterm dengan berat lahir bayi, kekuatan hubungan lemah (r=0,258), secara statistik tidak bermakna (p=0,161). Terdapat hubungan positif antara kadar HDL serum ibu hamil aterm, kekuatan hubungan sangat lemah (r=0,035), secara statistik tidak bermakna (p=0,850). Kesimpulan penelitian tidak terdapat hubungan kadar LDL dan HDL serum ibu hamil dengan berat lahir bayi.Kata kunci: kadar LDL serum, kadar HDL serum, ibu hamil aterm, berat lahir bayiAbstractMany studies proved that the transferring of cholesterol from mother to fetus through the trophoblastic layer carried LDL (Low Density Lipoprotein) and HDL (High Density Lipoprotein) particles. Uptake and usage of LDL by placenta to the fetus is an alternative mechanism to obtain fatty acids and essential amino acids. The objective of this study was to determine whether there is a relationship between LDL and HDL serum level of pregnant women at term with infant birth weight. This study was an observational study with cross sectional design. Examination of LDL and HDL serum level to 31 term pregnancy sample choose by consecutive sampling, and then infant’s birth weight was counted within 1 hour after birth without clothes. The data analyzed with Pearson correlation statistical test followed by simple linier regression statistical test. The mean of LDL serum level term pregnancy was 138,52±37,86mg/dlwith7 samples(22.60%) in LDL levels<101 mg/dl. The mean of HDL serum level at term pregnancy was 53,32±17,39 mg/dlwith 13 samples (41,90%) in HDL levels<48 mg/dl. The mean of infant birth weight was 3150,00±489,89 grams with 2 samples (6,50%) had infants weighing < 2500 grams. There is a positive relationship between LDL serum levels term pregnancy with birth weight infants, the strength of the relationship is weak (r =0,258), were not significant statistically (p=0,161). There is a positive relationship between HDL serum levels at term pregnancy with birth weight infants, the strength ofthe relationshipis veryweak(r =0,035), were not significant statistically (p=0,850). In conclusion there was no correlation of serum levels of LDL and HDL at term pregnant with birth weight.

ABNORMAL RESPONSE OF THYROTROPHIN AND GROWTH HORMONE TO THYROTROPHIN RELEASING HORMONE IN CHRONIC RENAL FAILURE

1975 ◽  
Vol 79 (4) ◽  
pp. 635-643 ◽  
Author(s):  
Koichi Hasegawa ◽  
Yoshiki Matsushita ◽  
Seima Otomo ◽  
Noboru Hamada ◽  
Yoshiki Nishizawa ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Healthy Subjects ◽  
Maximum Level ◽  
Serum Levels ◽  
Thyrotrophin Releasing Hormone ◽  
The Mean ◽  
Maximum Increment ◽  
Serum Gh ◽  
Serum Tsh

ABSTRACT Serum levels of TSH and GH were measured by radioimmunoassay after iv injection of 500 μg of TRH in 9 undialysed patients and 12 dialysed patients with chronic renal failure and in 6 healthy subjects. The basal level of the serum TSH was significantly higher in patients with chronic renal failure than that in healthy subjects. In healthy subjects, serum TSH rose to a maximum level 30 min after TRH injection, while in patients with chronic renal failure, serum TSH rose to a maximum level 60 min after TRH injection. The mean maximum increment of serum TSH in healthy subjects was significantly higher than that in patients with chronic renal failure. Although TSH levels rapidly decreased after initial rise at 30 min after TRH administration in healthy subjects, these did not show significant changes at 60 and 120 min compared with values at 30 min after TRH administration in both dialysed and undialysed patients. The basal level of serum GH was significantly higher in dialysed patients with chronic renal failure than in healthy subjects. Serum GH level was much higher in dialysed patients at 30 min after TRH injection compared with that in healthy subjects. These findings may indicate that the response of the pituitary to TRH is abnormal and that the turnover of TSH and GH is decreased in patients with chronic renal failure.

Low basal thyrotropin with normal thyroid function in primary hyperparathyroidism

1989 ◽  
Vol 121 (5) ◽  
pp. 638-642 ◽  
Author(s):  
Clementine Gillet ◽  
Pierre Bergmann ◽  
Dominique Francois ◽  
Jean-Jacques Body ◽  
Jacques Corvilain
Keyword(s):  
Primary Hyperparathyroidism ◽  
Thyroid Function ◽  
Serum Calcium ◽  
Normal Subjects ◽  
Serum Levels ◽  
Normal Thyroid Function ◽  
Basal Serum ◽  
Highly Correlated ◽  
Serum Tsh ◽  
Age And Sex

Abstract. TSH serum levels and thyroid function in 32 patients with primary hyperparathyroidism and hypercalcemia were compared to those of 30 age and sex-matched normal subjects. Serum T3 and T4 concentrations in hyperparathyroidism were not different from normal. However, basal serum TSH concentrations measured with an ultrasensitive immunoradiometric assay were significantly lower than normal (1.09 ± 0.49 vs 2.06 ± 0.85 mU/l, p < 0.001). In hyperparathyroidism, TSH, but not T4 or T3, was negatively correlated with serum calcium, not with iPTH. The increase in TSH (Δ TSH) 30 min after the iv injection of TRH was also significantly blunted in patients with primary hyperparathyroidism; Δ TSH was highly correlated with basal TSH in hypercalcemic patients. The basal TSH concentration was higher and no longer different from normal (1.70 ± 1.2 mU/l) 2 to 12 months after removal of the parathyroid adenoma, when serum calcium was normalized, whereas T3 and T4 did not change. A low basal TSH with normal T4 and low T3 was found in 13 patients with hypercalcemia of malignancy. In these patients, TSH increased after treatment of hypercalcemia with 3-amino-1,hydroxypropylidene-1,1-bisphosphonate, whereas T4 did not change. The results suggest that the set point of pituitary thyroid feedback control could be decreased in chronic hypercalcemia and that hypercalcemia could render the thyroid more sensitive to TSH.

scholarly journals Serum Levels of Growth Differentiation Factor-15 as an Inflammatory Marker in Patients with Unstable Angina Pectoris

2021 ◽  
Author(s):  
Fariba Raygan ◽  
Aniseh Etminan ◽  
Hanieh Mohammadi ◽  
Hossein Akbari ◽  
Hassan Nikoueinejad
Keyword(s):  
Angina Pectoris ◽  
Serum Level ◽  
Unstable Angina ◽  
Serum Levels ◽  
Unstable Angina Pectoris ◽  
Risk Scores ◽  
Growth Differentiation Factor 15 ◽  
Differentiation Factor ◽  
The Mean ◽  
And Control

Background: Growth differentiation factor-15 (GDF-15), a member of transforming growth factors, is a stress-responsive marker whose levels may significantly increase in response to pathological stresses associated with inflammatory tissue injuries such as unstable angina pectoris (USAP). This study evaluated the diagnostic value of GDF-15 in patients with USAP. Methods: The present cross-sectional study recruited 39 patients with USAP criteria and 30 patients with stable angina pectoris (SAP), referred to Shahid Beheshti Hospital, Kashan, Iran. All the patients with USAP had at least 1 coronary artery stenosis (>50%) in angiography. The control group comprised 42 healthy individuals. The serum levels of GDF-15 were measured in all the participants by ELISA. Also analyzed were the relationship between GDF-15 levels and thrombolysis in myocardial infarction (TIMI) and the Global Registry of Acute Coronary Events (GRACE) risk scores in the patients with USAP to determine the severity of the disease. Result: The study population consisted of 111 subjects, 62 women and 49 men, divided into 3 groups of USAP (n=39, mean age=60.07±14.10 y), SAP (n=30, mean age=67.56±9.88 y), and control (n=42, mean age=61.21±7.76 y). The mean serum level of GDF-15 in the USAP group was significantly different from the other 2 groups (P<0.001), while no significant difference was observed in this regard between the SAP and control groups (P=0.797). No correlation was found between the mean GDF-15 serum level and the GRACE (P=0.816) and TIMI (P=0.359) risk scores in the USAP group. Conclusion:  The mean serum level of GDF-15 exhibited a rise in our patients with USAP. GDF-15 may be a diagnostic biomarker of USAP and its severity.

The Relationship Between Serum Orexin A, TGF-β, and Leptin Levels with Body Mass Index in Multiple Sclerosis Patients

2021 ◽  
Author(s):  
Sepideh Moharami ◽  
Alireza Nourazarian ◽  
Masoud Nikanfar ◽  
Delara Laghousi ◽  
behrouz shademan ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Serum Level ◽  
Serum Levels ◽  
Healthy Controls ◽  
Control Groups ◽  
Orexin A ◽  
The Mean ◽  
Multiple Sclerosis Patients ◽  
And Control ◽  
The Relationship

Abstract Backgrounds: Multiple Sclerosis (MS) is a chronic inflammatory and autoimmune disease linked to several inflammatory and dietary parameters. This study was carried out to determine the relationship between serum leptin, orexin-A, and TGF-β levels with BMI in MS patients.Methods and results: In this cross-sectional study, 25 relapsing-remitting multiple sclerosis (RRMS) patients and 40 healthy controls were enrolled. The serum level of Leptin, Orexin-A, and TGF- were measured by the Enzyme-linked immunosorbent assay (ELISA). The data was analyzed using descriptive statistics, t-test, Chi-square test, and Linear regression test. A total of 65 volunteers, including 25 MS patients and 40 healthy, were enrolled in the study. The mean age of individuals in the case and control groups was 38.04 ± 7.53 and 40.23 ± 5.88. There were no statistically significant differences between the case and control groups regarding gender, age, alcohol, and cigarette use (P>0.05). The mean serum levels of Orexin-A and TGF-ß were lower among multiple sclerosis patients than in healthy controls, but leptin was higher (42.8 vs. 18.9 ng/ml, P<0.001). The relationship between BMI and serum levels of Orexin-A, TGF-ß, and Leptin among Multiple Sclerosis patients was not statistically significant (P > 0.05).Conclusion: Our results showed that the serum levels of Orexin-A and TGF-β were significantly lower. The serum level of leptin was higher among multiple sclerosis patients than among healthy controls. Also, there was no statistically significant relationship between BMI and serum levels of Orexin-A, TGF-ß, and Leptin among multiple sclerosis patients.

scholarly journals Comparative Study of Salivary and Serum Levels of Vitamin D in Patients with a History of High Blood Pressure and Healthy People

2018 ◽  
Vol 8 (1) ◽  
pp. 101 ◽  
Author(s):  
Hamidreza Abdolsamadi ◽  
Mohammad vahedi ◽  
Farnaz Fariba ◽  
Alireza Soltanian ◽  
Meghdad Zakavati Avval ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Vitamin D ◽  
Serum Level ◽  
High Blood Pressure ◽  
Healthy Subjects ◽  
Serum Levels ◽  
Vitamin D Levels ◽  
Significant Difference ◽  
History Of ◽  
The Mean

Introduction: Vitamin D deficiency is a major public health problem. Low vitamin D levels associated with adverse health consequences such as musculoskeletal health, cognitive decline and progression of cancer and death. The lack of vitamin D associated with major risk factors for cardiovascular disease (CVD) includes hypertension is considered. The ability to assess the general health, disease and treatment outcomes through saliva as a non-invasive, inexpensive and simple method of interest is located. The aim of this study was a comparative study of salivary and serum levels of vitamin D3 in patients with a history of developing high blood pressure and a healthy person.Methods: This study was a case - control survey, in which 40 patients with high blood pressure were examined. The control group including 40 healthy subjects. Both groups were matched in terms of age and gender. After collecting samples of serum and saliva, the amount of vitamin D level samples were measured using ELISA method by electrochemiluminescence (ELC), and then analyzed the results using software SPSS 16 and statistical test including Chi Square Test, Independent-Samples, linear regression model, the Mann-Whitney Test and Spearman correlation coefficient.Results: There was no significant difference in the mean serum levels of vitamin D among patients and healthy subjects (p= 0.588). In addition, there was no significant difference in the mean salivary levels of vitamin D between patients and healthy subjects (p= 0.833). There was no significant relationship between salivary and serum level of vitamin D in healthy individuals (p= 0.095). As well as there was no significant correlation between salivary and serum level of vitamin D in patients (p= 0.5).Conclusions: This study showed that vitamin D is a measurable marker in saliva, but its analysis in saliva, may not be a reliable tool for determining the vitamin D levels.

Influence of dopaminergic inhibition on serum levels of thyrotrophin and prolactin in patients with hypothyroidism before and after prolonged oral administration of TRH

1983 ◽  
Vol 104 (2) ◽  
pp. 183-188 ◽  
Author(s):  
Harald M. M. Frey ◽  
Egil Haug
Keyword(s):  
Oral Administration ◽  
Serum Levels ◽  
Primary Hypothyroidism ◽  
Dopamine Antagonist ◽  
Trh Stimulation ◽  
Before And After ◽  
The Mean ◽  
Pre Treatment ◽  
Serum Tsh

Abstract. Forty mg TRH/day given orally for 3 weeks to 8 patients with mild primary hypothyroidism decreased serum TSH from a mean of 4.0 ng/ml ± 1.2 (se) to 2.0 ng/ml ± 0.4 (49%), and their mean incremental TSH response to iv TRH was equally reduced from 8.6 ng/ml ± 2.5 to 4.0 ng/ml ± 1.9 (46%). In the same patients serum Prl was 8.2 ng/ml ± 2.2 before oral TRH treatment and 6.6 ng/ml ± 1.5 (81%) after treatment, and the mean incremetal Prl response to iv TRH was reduced from 43.5 ng/ml ± 5.0 to 35.9 ng/ml ± 7.5(83%). The oral administration of 10 mg of the dopamine antagonist metoclopramide increased mean serum TSH from 0.6 ng/ml ± 0.1 (se) to 0.7 ng/ml ± 0.1 (120%) in euthyroid subjects and from 4.0 ng/ml ±1.2 to 5.7 ng/ml ± 1.6 (145%) in patients with primary hypothyroidism, and mean serum Prl from 8.6 ng/ml ± 0.8 to 109.5 ng/ml ± 24.3 (1251%) and from 8.2 ng/ml ± 2.2 to 119.6 ng/ml ± 45.5(1460%), respectively. The incremental TSH responses to iv TRH increased 2.3-fold in euthyroid subjects pre-treated with metoclopramide, while no change was observed in the TSH responsiveness in patients with primary hypothyroidism following metoclopramide pre-treatment. In the euthyroid subjects metoclopramide treatment had no effect on the Prl response to iv TRH. In the primary hypothyroid group metoclopramide pre-treatment caused a reduced Prl response to iv TRH in more than 50% of the patients. It is concluded that long-term TRH treatment decreased the serum levels of TSH and Prl as well as the incremental increases in TSH and Prl to iv TRH stimulation in patients with primary hypothyroidism. Long-term TRH treatment did not change the TSH and Prl responses to the dopamine antagonist metoclopramide.

PITUITARY-THYROID FUNCTION IN SPIRONOLACTONE TREATED HYPERTENSIVE WOMEN

1979 ◽  
Vol 90 (3) ◽  
pp. 577-584 ◽  
Author(s):  
A. G. H. Smals ◽  
P. W. C. Kloppenborg ◽  
W. H. L. Hoefnagels ◽  
J. I. M. Drayer
Keyword(s):  
Thyroid Function ◽  
Bolus Injection ◽  
Serum Testosterone ◽  
High Dose ◽  
Enhancing Effect ◽  
Basal Serum ◽  
The Mean ◽  
17 Hydroxyprogesterone ◽  
Lh Rh ◽  
Serum Tsh

ABSTRACT Four weeks high dose spironolactone treatment (Aldactone® Searle, 100 mg q. i. d.) significantly enhanced the TSH (Δ max. 8.5 ± 4.1 vs. 4.6 ± 3.1 μU/ml, P < 0.05) and T3 (Δ max. 32±27 vs. 11 ± 16 ng/100 ml, P < 0.05) responses to an intravenous TRH/LH-RH bolus injection in 6 eumenorrhoeic euthyroid hypertensive women, without affecting basal serum TSH, T3 or T4 levels or the basal and stimulated LH, FSH and prolactin values (P > 0.10). The mean serum testosterone, 17-hydroxyprogesterone and oestradiol levels were also similar before and during therapy. Spironolactone, possibly by virtue of its antiandrogenic action, may exert its enhancing effect on pituitary-thyroid function by modulating the levels of receptors for TRH in the thyrotrophs or by altering the T3 receptor in the pituitary permitting a greater response to TRH.

scholarly journals Study the association of testosterone levels with insulin resistance in Iraqi men with Diabetes mellitus type 2

2015 ◽  
Vol 9 (1) ◽  
pp. 4-12
Author(s):  
Ali Haider Alhammer
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Serum Level ◽  
Free Testosterone ◽  
Serum Levels ◽  
Diabetic Group ◽  
Total Testosterone ◽  
C Peptide ◽  
The Mean

This study was set to evaluate the testosterone serum levels and their association with insulin resistance to uncover if any related possible negative consequences in Iraqi patients with Diabetes mellitus (DM). Sixty six men with type 2 DM were randomly selected and compared to 18 healthy volunteers, demographic data were collected in addition to 10 ml of venous blood was drawn to evaluate serum levels of total Testosterone (T), free testosterone (FT), c-peptide, Sex Hormone Binding Globulin (SHBG), lipid profile, and blood sugar. The mean serum level of total testosterone was 2.434 ± 0.12 ng/ml in diabetic patients and 3.62 ± 0.32 ng/ml in non-diabetic subjects which was significantly different (p=0.003). The mean value of free serum level of testosterone was significantly higher in non-diabetic group (14.71 ± 1.4 pg/ml) in comparison with diabetic group (10.71 ± 0.54 pg/ml; p=0.017). Total testosterone correlates positively with FT and SHBG, while negatively with c-peptide, age and Body mass index (BMI). It’s concluded that total testosterone, free testosterone, and SHBG were significantly lower in diabetic group which strongly associated with insulin resistance.

Sign in / Sign up

Export Citation Format

Share Document